Dixestivo
Servizo
Instituto de Investigación Sanitaria La Fe
Valencia, EspañaPublicacións en colaboración con investigadores/as de Instituto de Investigación Sanitaria La Fe (18)
2024
-
Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir
Alimentary Pharmacology and Therapeutics
2023
-
Budesonide as first-line treatment in patients with autoimmune hepatitis seems inferior to standard predniso(lo)ne administration
Hepatology, Vol. 77, Núm. 4, pp. 1095-1105
-
Inadequate social support decreases survival in decompensated liver cirrhosis patients
Gastroenterologia y Hepatologia, Vol. 46, Núm. 1, pp. 28-38
-
Significant heterogeneity in the diagnosis and long-term management of Wilson disease: Results from a large multicenter Spanish study
Gastroenterologia y Hepatologia, Vol. 46, Núm. 8, pp. 577-584
2022
-
Consensus Statement on Hemostatic Management, Anticoagulation, and Antiplatelet Therapy in Liver Transplantation
Transplantation, Vol. 106, Núm. 6, pp. 1123-1131
2021
-
Incidence, clinical characteristics and management of inflammatory bowel disease in spain: Large-scale epidemiological study
Journal of Clinical Medicine, Vol. 10, Núm. 13
-
Obeticholic Acid and Fibrates in Primary Biliary Cholangitis: Comparative Effects in a Multicentric Observational Study
American Journal of Gastroenterology, Vol. 116, Núm. 11, pp. 2250-2257
2020
-
Erratum to: “Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH (J Hepatol 2020; 73: 17–25) (Journal of Hepatology (2020) 73(1) (17–25), (S0168827820301276), (10.1016/j.jhep.2020.02.028))
Journal of Hepatology
-
Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH
Journal of Hepatology, Vol. 73, Núm. 1, pp. 17-25
-
The Harvey-Bradshaw Index Adapted to a Mobile Application Compared with In-Clinic Assessment: The MediCrohn Study
Telemedicine and e-Health, Vol. 26, Núm. 1, pp. 80-88
2019
-
Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial
Digestive and Liver Disease, Vol. 51, Núm. 4, pp. 529-535
2017
-
Adalimumab Maintenance Treatment in Ulcerative Colitis: Outcomes by Prior Anti-TNF Use and Efficacy of Dose Escalation
Digestive Diseases and Sciences, Vol. 62, Núm. 2, pp. 481-490
-
Distribution and genotype-phenotype correlation of GDAP1 mutations in Spain
Scientific Reports, Vol. 7, Núm. 1
2016
-
Outcome after a dose "de-intensification" strategy with anti-TNF drugs in patients with Crohn's disease
Gastroenterologia y Hepatologia, Vol. 39, Núm. 4, pp. 255-260
-
The Fanconi anemia DNA damage repair pathway in the spotlight for germline predisposition to colorectal cancer
European Journal of Human Genetics, Vol. 24, Núm. 10, pp. 1501-1505
2015
-
Response to infliximab in Crohn's disease: Genetic analysis supporting expression profile
Mediators of Inflammation, Vol. 2015
2014
-
Role of TNFRSF1B polymorphisms in the response of Crohn's disease patients to infliximab
Human Immunology, Vol. 75, Núm. 1, pp. 71-75
2013
-
Safety of thiopurine therapy in inflammatory bowel disease: Long-term follow-up study of 3931 patients
Inflammatory Bowel Diseases, Vol. 19, Núm. 7, pp. 1404-1410